Clinical trials: ASD II
Autism Spectrum Disorder
Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)
A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)
- Trial name
- NCT05791071
- Testing
- Floreo VR Building Social Connections
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Floreo, Inc.
Autism Spectrum Disorder
Arbaclofen in Children and Adolescents With ASD
AIMS-2-CT-01 is a randomized, double-blind, placebo controlled, study to explore the efficacy, safety and tolerability of Arbaclofen administered to children and adolescents (ages 5-17) for the treatment of social adaptive…
- Trial name
- AIMS2-CT1 (NCT03682978)
- Testing
- Arbaclofen
- Where
- 7 sites in France, Spain and 1 more
- Volunteers
- 124 people
- Sponsor
- Celso Arango, MD, PhD
Autism, Autistic Disorder
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in…
- Conditions
- Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases
- Trial name
- NCT00110708
- Testing
- Oralgam (human immunoglobulin)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- PediaMed Pharmaceuticals
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Secundum Atrial Septal Defects
Occlutech Septal Occluder (Figulla Flex II) Study
The objectives of the study are: To determine the efficacy of the Figulla Flex II device compared with that of the Amplatzer ASO device for transcatheter closure of secundum atrial septal defects To determine the safety of the…
- Trial name
- NCT04488120
- Testing
- transcatheter closure of secundum atrial septal defects in patients
- Volunteers
- 175 people
- Sponsor
- Occlutech International AB
Autism Spectrum Disorder
Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract < 0.08% THC (FEN164) in children with Autism Spectrum Disorder.
- Trial name
- NCT05516407
- Testing
- FEN164
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
Autism Spectrum Disorder (ASD)
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
- Trial name
- NCT06757504
- Testing
- TTYP01 Tablets (12mg or 18mg)
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Autism Spectrum Disorder (ASD)
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of >/=50 on the Wechsler Abreviated Scale of…
- Trial name
- NCT04299464
- Testing
- RO7017773
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Autistic Disorder
Sapropterin as a Treatment for Autistic Disorder
This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in…
- Trial name
- NCT00850070
- Testing
- sapropterin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Children's Health Council
Autism, Autism Spectrum Disorder
hCT-MSC in Children With Autism Spectrum Disorder
The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder…
- Trial name
- IMPACT (NCT04089579)
- Testing
- Cord Tissue Mesenchymal Stromal Cells
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Joanne Kurtzberg, MD
ASD II, Percutaneous Closure
Echocardiography-guided Oval-shaped ASD Closure
Background: An atrial septal defect (ASD) is considered oval-shaped when its shortest diameter is less than 75% of its longest diameter.
- Conditions
- ASD II, Percutaneous Closure, Zero-fluoroscopy
- Trial name
- NCT06526403
- Testing
- Zero-fluoroscopy ASD closure
- Where
- Indonesia
- Volunteers
- 78 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Autism Spectrum Disorder
Early Connections, Early Detection and Intervention in Infants at Risk for Autism
Early connections has two broad goals: to identify risk indices for autism spectrum disorder (ASD) in 6 to 24 month old infants who have an older sibling with ASD or infants who have an older neurotypical sibling.
- Trial name
- NCT00947700
- Testing
- Assessment, Monitoring & Intervention
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Washington
Atrial Septal Defect
Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy
A prospective, multicenter, randomized controlled, non-inferiority clinical trial to evaluate the safety and efficacy of the AbsnowTM II absorbable atrial septal defect occluder system for atrial septal defect closure therapy.
- Trial name
- NCT07529028
- Testing
- Absnow II Absorbable Atrial Septal Defect Occluder System, Cera Atrial Septal Defect Occluder
- Volunteers
- 236 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Fragile X Syndrome
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
- Trial name
- NCT01894958
- Testing
- NNZ-2566
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Neuren Pharmaceuticals Limited
Rett Syndrome
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
- Trial name
- NCT01703533
- Testing
- NNZ-2566
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuren Pharmaceuticals Limited
Autism Spectrum Disorder
Acupressure and Acupuncture as an Intervention With Children With Autism II
The purpose of this study is to see if children with autism spectrum disorder (ASD) will tolerate an acupressure and acupuncture intervention twice weekly over a 3 month period of time that targets regulatory and behavioral…
- Trial name
- NCT00935701
- Testing
- Acupressure and Acupuncture
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Ostium Secundum Atrial Septal Defect
Occluder Size Determination in Transcatheter ASD II Closure Based on 3D TEE Assessment
The aim of this study is to determine whether three-dimensional tranesophageal echocardiography (3D TEE) assessment of ostium secundum atrial septal defect (ASD II) may be as efficient as two-dimensional (2D) TEE assessment…
- Trial name
- NCT02601768
- Testing
- Transcatheter closure of ASD II
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Fragile X Syndrome
Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome
The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability.
- Trial name
- SXF-TRA152 (NCT01329770)
- Testing
- Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Yolanda de Diego Otero
Autism Spectrum Disorder (ASD
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum…
- Trial name
- NCT06951854
- Testing
- Drug: NV01-A02
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Neuroventi Inc.
ASD II
Holter and ECG Changes After Trancatheter Closure Of ASD In Children
Atrial septal defects (ASD) account for 10% of all congenital heart defects . Hemodynamic consequences of an ASD are dilatation of the right atrium and right ventricle (RV) because of the volume overload due to the left-to-right…
- Trial name
- NCT06197191
- Testing
- Fukuda Denshi Cardimax ECG device model FCP-7101
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University